Floatz logo

889 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ami-Lc-Md
Neoplasm
Janssen Research & Development, LLCP1C (37)
Amivantamab-Vmjw
Neoplasm
ORIC PharmaceuticalsP1C (37)
Anti-B7-H3 Chimeric Antigen Receptor T-Cell /Tx103
Neoplasm
Tcelltech Inc.P1C (37)
Ast-201
Neoplasm
Aptamer Sciences, Inc.P1C (37)
Atlcar.Cd30.Ccr4 Cells
Neoplasm
UNC Lineberger Comprehensive Cancer CenterP1C (37)
Atv-1601
Neoplasm
Atavistik Bio, IncP1C (37)
Aube00
Neoplasm
Chugai PharmaceuticalP1C (37)
ba1106
Neoplasm
Shandong Boan Biotechnology Co., LtdP1C (37)
Bg-C0902
Neoplasm
BeOne MedicinesP1C (37)
bi 1703880
Neoplasm
Boehringer IngelheimP1C (37)
bi 1821736
Neoplasm
Boehringer IngelheimP1C (37)
bi 1831169
Neoplasm
Boehringer IngelheimP1C (37)
bi 3923948
Neoplasm
Boehringer IngelheimP1C (37)
bi 765179
Neoplasm
Boehringer IngelheimP1C (37)
bi 770371
Neoplasm
Boehringer IngelheimP1C (37)
Bl-Arc002
Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.P1C (37)
Blu-701
Neoplasm
Blueprint Medicines CorporationP1C (37)
Budigalimab
Neoplasm
AbbVieP1C (37)
Casdatifan
Neoplasm
Arcus Biosciences, Inc.P1C (37)
Cba-1205
Neoplasm
Chiome Bioscience Inc.P1C (37)
Cba-1535
Neoplasm
Chiome Bioscience Inc.P1C (37)
cs231295
Neoplasm
Chipscreen Biosciences, Ltd.P1C (37)
cx-904
Neoplasm
CytomX TherapeuticsP1C (37)
D-Ala-D-Ala-Leu-Pro-Ile-Pro-Leu-Asp-Gln-Thr-D-Ala-D-Ala-Nh2
Neoplasm
SparX Biotech(Jiangsu) Co., Ltd.P1C (37)
Dptx3186
Neoplasm
Dewpoint TherapeuticsP1C (37)
ds-2243a
Neoplasm
Daiichi SankyoP1C (37)
ds3610a
Neoplasm
Daiichi SankyoP1C (37)
Egfr/B7H3 Car-T
Neoplasm
National Cancer Institute (NCI)P1C (37)
Etc-159
Neoplasm
EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesP1C (37)
ftl008.16
Neoplasm
Sound Biopharmaceuticals Ltd.P1C (37)
FXB0871
Neoplasm
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.P1C (37)
G 207
Neoplasm
M.D. Anderson Cancer CenterP1C (37)
gen1106
Neoplasm
GenmabP1C (37)
gk01
Neoplasm
Tianjin Medical University Cancer Institute and HospitalP1C (37)
gs-9911
Neoplasm
Gilead SciencesP1C (37)
gsk3745417
Neoplasm
GlaxoSmithKlineP1C (37)
gsk5533524
Neoplasm
GlaxoSmithKlineP1C (37)
gsk5733584
Neoplasm
GlaxoSmithKlineP1C (37)
GSK5764227
Neoplasm
GlaxoSmithKlineP1C (37)
hdm2017
Neoplasm
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.P1C (37)
Hrs-6208
Neoplasm
Shandong Suncadia Medicine Co., Ltd.P1C (37)
hs-20110
Neoplasm
Hansoh BioMedical R&D CompanyP1C (37)
hsk42360
Neoplasm
Haisco Pharmaceutical Group Co., Ltd.P1C (37)
ibi3020
Neoplasm
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.P1C (37)
Immunoglobulin G1 [143-Aspartic Acid,236-Glutamic Acid], Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Hbm4003 Heavy Chain V-D-J Region) Fusion Protein With Immunoglobulin G1 (Human ?1-Chain C Region), Dimer
Neoplasm
Harbour BioMed (Guangzhou) Co. Ltd.P1C (37)
Immunoglobulin G4, Anti-(Human Cd3 Antigen) (Recombinant Human Monoclonal Jnj-75348780 ?4-Chain), Disulfide With Recombinant Human Monoclonal Jnj-75348780 ? Chain, (229?126?),(232?129?)-Bis(Disulfide) With Immunoglobulin, Anti-(Human Sialic Acid-Binding Ig-Like Lectin 2) (Recombinant Human Single-Domain Vhh Fragment)
Neoplasm
Janssen Research & Development, LLCP1C (37)
Imp-321
Neoplasm
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestP1C (37)
Inca036873
Neoplasm
Incyte CorporationP1C (37)
Inca33890
Neoplasm
Incyte CorporationP1C (37)
Incb123667
Neoplasm
Incyte CorporationP1C (37)
Showing 551 to 600 of 889 assets
PreviousPage 12 of 18Next